They have realistic expectations: they are not expecting a return to the early dramatic phase of GLP-1 weight loss, but rather a renewed period of modest progress through what would otherwise be a flat curve
How do I know what concentration to make my AHK-Cu solution
Potential risks include: Infection risk if injections are administered in non-clinical settings without appropriate sterile technique Allergic reactions to any component of the formulation Liver toxicity theoretical concern with excessive methionine or choline Drug interactions particularly if combined with other supplements or medications Unknown long-term effects due to absence of longitudinal safety data The MHRA advises caution with unlicensed injectable products, as quality, purity, and sterility cannot be guaranteed
Inadequate dietary intake
We know that macrocytosis is a very, very late stage of B12 deficiency and that severely deficient patients may not present with this sign, the administration of folic acid also masks macrocytosis by normalising the size of the blood cells
The answer is thermal degradation, not biological variability